A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients
PHASE1CompletedINTERVENTIONAL
Enrollment
27
Participants
Timeline
Start Date
October 4, 2016
Primary Completion Date
November 30, 2018
Study Completion Date
November 30, 2018
Conditions
Solid TumorLymphoma
Interventions
DRUG
Tripegfilgrastim
Trial Locations (1)
82
Seoul National University Hospital, Seoul
All Listed Sponsors
lead
Dong-A ST Co., Ltd.
INDUSTRY
NCT02963389 - A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients | Biotech Hunter | Biotech Hunter